Chinese COVID-19 vaccine enters third-stage human trial

Oxford Vaccine Safe And Effective In Older Adults As Well, Phase 2 Data Shows

Competition has intensified among pharmaceutical companies racing to develop a Covid-19 shot, with two vaccines - one by United States company Pfizer and its German partner BioNTech, and another by U.S. firm Moderna - publishing large-scale trial data this month that showed their jabs were around 95 percent effective against Covid-19.

According to the research, the adverse reactions were mild. There have been many examples of 100 percent of people who have not been infected with the corona by getting this vaccine.

Mr Liu said the vaccine had been given to Chinese construction workers, diplomats, and students who have gone to more than 150 countries around the world during the pandemic - and none of them has reported an infection.

The experimental vaccines are undergoing Phase 3 clinical trials overseas that have recruited almost 60,000 people, and blood samples of more than 40,000 participants have been taken 14 days after they took the second dose, the article said citing Liu, without breaking down the numbers for each vaccine.

Asked about when the efficacy data for the vaccine, AZD1222/ ChAdOx1 nCoV-19, is expected, Pollard told BBC Radio: "We haven't quite got to that point yet".

A COVID-19 vaccine under development at Oxford University in England appears safe and triggers an immune response in older adults, researchers report.

Despite recent progress, Pollard said the world is still in the early stages of the effort to protect people against COVID-19. CNN has not seen the results of these trials yet.

Beijing has granted approval to companies for urgent vaccinations using experimental drugs for months.

Almost a million people in China have taken an experimental coronavirus vaccine through the country's emergency use program as of Wednesday, according to vaccine developer China National Pharmaceutical Group (Sinopharm).

AstraZeneca and Oxford's vaccine works differently than the one created by Pfizer and Moderna.

Top US disease expert, Dr Anthony Fauci, said Moderna and Pfizer vaccines are promising.

ChAdOx1 nCov-2019 vaccine is now undergoing its Phase 3 trial with 40,051 participants now enrolled.

Sinopharm has yet to comment which vaccines were used in the emergency program and Jingzhen was unclear about which vaccine he was addressing.

"That is extraordinary", Dr Fauci said.



Other news